Extrawell Pharmaceutical Holdings Limited (Extrawell) is an investment holding company that operates through four business segments, namely, manufacturing, trading, gene development and oral insulin. The company operates in these segments through its subsidiaries, Changchun Extrawell Pharmaceutical Co. Ltd. (CEPL), Jilin Extrawell Changbaishan Pharmaceutical Co. Ltd. (JECPL), South Asia Pharmaceutical (China) Ltd. (SAPL), Right & Rise Ltd. and Smart Ascent Ltd. (SAL). CEPL is engaged in selling 6 major biological products, principally in immunological, cardiovascular, dermatological and antithrombotics categories. JECPL is engaged in selling and distributing 8 major products in the market which are used in the treatment of immunological, cardiovascular and pulmonary diseases. SAPL is engaged in distributing imported pharmaceuticals which focus on central nervous system, antihypertensive and dermatology categories. Right & Rise Ltd. has 19 items of diabetic related gene patent rights. SAL is focused on the development and commercialization of oral insulin product. Extrawell is headquartered in Wanchai, Hong Kong.